Hem › Kronisk lymfatisk leukemi › New York › New York City
Kliniska studier för Kronisk lymfatisk leukemi i New York City, NY
19 studier för Kronisk lymfatisk leukemi söker deltagare vid platser i och runt New York City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
RekryterarFas 2
- NYP/Weill Cornell Medical Center, New York
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekryterarFas 3
- Memorial Sloan Kettering Cancer Center, New York
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekryterarFas 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekryterarObservationsstudieFriska volontärer välkomna
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RekryterarFas 1/2
- Research Site, New York
- Research Site, New York
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekryterarFas 3
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RekryterarFas 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekryterarFas 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RekryterarFas 3
- Columbia University Medical Center, New York
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RekryterarFas 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekryterarFas 3
- David H. Koch Center for Cancer Care, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekryterarFas 1/2
- Research Site, New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 1
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
RekryterarFas 2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai /ID# 266328, New York
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
RekryterarFas 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekryterarFas 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekryterarFas 4
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
RekryterarFas 1
- Weill Cornell, New York
Kronisk lymfatisk leukemi-studier i andra städer
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Cincinnati, OH14 studier
- Chicago, IL14 studier
- Nashville, TN13 studier
Andra studier i New York City
- Bröstcancer137 studier
- Icke-småcellig lungcancer121 studier
- Cancer (alla typer)110 studier
- Prostatacancer102 studier
- Metastaserande cancer93 studier
- Kolorektal cancer78 studier
- Äggstockscancer70 studier
- Bukspottkörtelcancer60 studier
- Multipelt myelom60 studier
- Lungcancer60 studier
- Endometriecancer52 studier
- Hjärtsvikt51 studier
Från ClinicalTrials.gov, data hämtad 7 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.